Xiaolan Fu
#109,724
Most Influential Person Now
Professor of economics
Xiaolan Fu's AcademicInfluence.com Rankings
Download Badge
Economics
Why Is Xiaolan Fu Influential?
(Suggest an Edit or Addition)According to Wikipedia, Professor Xiaolan Fu is a British-based Chinese economist, and Fellow of the Academy of Social Sciences. She is the Founding Director of the Technology and Management Centre for Development . She is a Professor of Technology and International Development and Fellow of Green Templeton College at the University of Oxford.
Xiaolan Fu's Published Works
Published Works
- Study of prognostic predictors for non-small cell lung cancer. (1999) (81)
- LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706) (2020) (8)
- MA 14.12 Detecting Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma Using Radiomics and Random Forest (2017) (3)
- [Application and prospect of artificial intelligence in cancer diagnosis and treatment]. (2018) (3)
- 127P A prospective phase II clinical trial exploring neoadjuvant immunotherapy combined with chemotherapy in resectable thoracic esophageal squamous cell cancer (TESCC) with multi-station lymph node metastases (NICE study): Preliminary results (2020) (3)
- Residual Error of the Online Kilovoltage Cone-Beam CT Guided Radiotherapy Evaluated in Phantom and Thoracic Cancer Patients (2007) (2)
- 179P The cytoplasmic LKB1 promotes the growth of human lung adenocarcinoma by enhancing autophagy (2018) (1)
- Concurrent Thoracic Radiotherapy (TRT) With Single-agent Gefitinib In Patients With Pre-treated IIIB/IV Non-small Cell Lung Cancer (NSCLC): Final Report of A Phase I Study With EGFR Mutation Analyses (2011) (1)
- Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy (2022) (1)
- Association between Polymorphisms in DNA Repair and Inflammatory Response Genes and Ctcae 3.0 Grade 2 or Worse Esophagitis Induced by Neoadjuvant Platinum-based Chemotherapy and Thoracic Radiotherapy (2010) (1)
- Phase I Dose Escalation Study of Thoracic Radiotherapy in Combination with Gefitinib in Patients with IIIB/IV Non-small Cell Lung Cancer (2010) (1)
- Involved-field radiotherapy for patients with limited small cell lung cancer: Patterns of local-regional failure and feasibility. (2009) (1)
- The Differential Impact of Postoperative Radiation Therapy for Completely Resected Stage IIIA (N2) Non-Small Cell Lung Cancer: Based on the Risk Prediction Model for Locoregional Recurrence (2016) (1)
- Management of Primary Thoracic Small Cell Esophageal Carcinoma: Analysis of 20 Consecutive Cases (2013) (1)
- Colorectal neuroendocrine carcinoma and colorectal mixed adeno-neuroendocrine carcinoma: A population-based study of the surveillance, epidemiology, and end results registry. (2018) (1)
- EP1.12-22 The Expression and Prognostic Roles of PD-L1, PAPR1 and DLL3 in Small Cell Lung Cancer (2019) (1)
- [Multivariate analysis for prognostic predictors in non-small cell lung cancer]. (2001) (1)
- A Randomized Phase 2 Trial Estimating the Optimal Radiation Volume of Postoperative Radiation Therapy for Patients With Locoregionally Advanced Thoracic Esophageal Squamous Cell Carcinoma—A Preliminary Report (NCT01391572) (2016) (0)
- Positron Emission Tomography–Based Radiomics Features May Be Prognostic of Outcome in Patients With Esophageal Squamous Cell Carcinoma Treated With Chemoradiation Therapy (2016) (0)
- P3.13-010 Correlation between HRCT Features of Pulmonary Pure Ground-Glass Nodules and the New Pathologic Classification of Lung Adenocarcinoma (2017) (0)
- Circulating tumor DNA dynamics to predict cancer recurrence/metastasis in Chinese pathologic stage I lung adenocarcinoma. (2020) (0)
- P21.15 Sparing Preserved Lobes to Reduce Lung Dose for Operable IIIA NSCLC Patients Treated with Neoadjuvant Chemoradiotherapy (2021) (0)
- P1.12-18 Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation (2018) (0)
- Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma (2022) (0)
- [Chemotherapy combined with chest radiation therapy in the treatment of 95 patients with limited stage small cell lung cancer]. (2000) (0)
- P29.03 Thoracic Organs at Risk (OARs) Contouring Variations and Consensus in Radiation Therapy for Non-Small Cell Lung Cancer (2021) (0)
- 113P Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication (2022) (0)
- P29.05 Gross Tumor Volume Contouring Variations in Radiation Therapy of Non-Small Cell Lung Cancer (2021) (0)
- Late Toxicities Differed Maximum Tolerated Dose Determined by Acute Toxicities: Reanalysis of a Phase I/II Trial of Dose Escalation in Unresectable Thoracic Esophageal Cancer by Simultaneous Integrated Boost (2018) (0)
- P17.01 Adaptive Elastic-Net Nomogram Predicting Disease-Free Survival in Resected Stage IIIA (N2) Non–Small Cell Lung Cancer (2021) (0)
- ePoster SessionsRole of Postoperative Radiotherapy in the Treatment of Adenoid Cystic Carcinoma of the Trachea and Bronchus with Positive Surgical Margin: Rethinking about the Resection Range (2017) (0)
- 70P A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs) (2022) (0)
- The Predictive Value of Exhaled Nitric Oxide in Symptomatic Radiation Pneumonitis after Thoracic Radiation Therapy (2017) (0)
- Impact of a Definition Bladder ITV on kVCBCT Tailored Adaptive Radiation Therapy in Bladder Cancer (2012) (0)
- MA 17.03 Prognostic Value of the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Completely Resected Stage IIIA(N2) NSCLC (2017) (0)
- JCSE01.20 Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation (2018) (0)
- 44P A large population-based study on large cell neuroendocrine lung cancer: A SEER database analysis (2018) (0)
- A Phase I Dose Escalation Study of Nimotuzumab in Combination with Concurrent Chemoradiotherapy for Patient with Locally Advanced Squamous Cell Cancer of Esophagus (ESO) (2011) (0)
- P47.18 Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial) (2021) (0)
- A comparison of efficacy and toxicity between never-smokers and smokers with lung adenocarcinoma after concurrent gefitinib and thoracic radiotherapy. (2010) (0)
- Clinical Value and Optimal Timing of Cranial Local Therapy among EGFR-Mutant Non-small-cell Lung Cancer with Brain Metastases in the Era of Osimertinib (2020) (0)
- MA 17.02 Clinical Impact of the Tumor Immune Microenvironment and Immunoscore in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer (2017) (0)
- P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy (2020) (0)
- Two-Field Lymph Node Dissection With Adjuvant Radiation Therapy Is Similar to 3-Field Lymph Node Dissection for Patients With Locoregionally Advanced Thoracic Esophageal Squamous Cell Carcinoma (2016) (0)
- Pattern of Lymph Node Metastases and its Implication in Radiotherapy in Patients with Thoracic Esophageal Squamous Cell Carcinoma (2011) (0)
- 19P Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/AKT pathway (2018) (0)
- Maximum tolerated radiation dose for unresectable thoracic esophageal squamous cell carcinoma: both acute and late toxicities matter. (2019) (0)
- Safety and Efficacy of Hypofractionated Radiotherapy and Concurrent Chemotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer (2020) (0)
- EP1.01-34 A Retrospective Study of the Pattern of Lymph Node Metastasis in Superior Sulcus Non-Small-Cell Lung Cancers (2019) (0)
- Phase I dose-escalation study of thoracic radiotherapy in combination with gefitinib in patients with IIIB/IV non-small cell lung cancer (NCT00497250). (2009) (0)
- Safety of Dose Escalation by Simultaneous Integrated Boosting Radiation Dose in Unresectable Stage III Non-Small Cell Lung Cancer (2016) (0)
- Feasibility and Safety of the Clinical Target Volume Design for Postoperative Radiation Therapy in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer: A Prospective Validation Study (2016) (0)
- P1.12-24 Comparison of Four Prognostic Scores for Patients with Brain Metastases from Small-Cell Lung Cancer (2019) (0)
- P20.02 To Evaluate the Efficacy and Optimal Timing of Postoperative Radiotherapy in Completely Resected stage IIIA(N2) Non-Small Cell Lung Cancer (2021) (0)
- Preliminary Results of Definitive Concurrent Chemoradiation Therapy With S-1 and Nedaplatin for Locally Advanced Esophageal Squamous Cell Carcinoma (2017) (0)
- Radiation-induced lung injury and misdiagnosis rate after SBRT (2019) (0)
- Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors (2019) (0)
- 969TiP Randomized, phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYVIBE-006 (2022) (0)
- Which One Is More Reasonable for Concurrent Chemoradiation of Thoracic Esophageal Squamous Cell Cancer, CTV-ENI or CTV-IFI? A Retrospective Study of Basing Postoperative Pathological Data (2016) (0)
- [Surgical treatment of laryngeal cancer]. (1988) (0)
- EP05.03-012 Deep Learning-based Classifier to Predict Intensified Locoregional Approach Need in Stage III Non-Small Cell Lung Cancer (2022) (0)
- [The effect of whole pleural cavity irradiation with combined 60Co and electron beam plus local biological agents on malignant pleural effusion]. (2000) (0)
- Prognostic Index for Estimating the Effect of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer: A Real-World Validation Study (2020) (0)
- Postoperative Radiation Therapy for Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Population Study from 1988 to 2014 Using the Surveillance, Epidemiology, and End Results Database (2018) (0)
This paper list is powered by the following services:
Other Resources About Xiaolan Fu
What Schools Are Affiliated With Xiaolan Fu?
Xiaolan Fu is affiliated with the following schools: